Cyramza® (ramucirumab): Tidigare användning av Sorafenib i REACH-2

Study Design

A global, randomized, double-blind, placebo-controlled study compared ramucirumab plus BSC and placebo plus BSC in patients with advanced HCC and elevated baseline AFP following first-line sorafenib.¹

Patients were stratified by

• geographic region (Americas, Europe, Israel, and Australia vs Asia [except Japan] vs Japan)

• baseline ECOG PS (0 vs 1), and

• macrovascular invasion (yes vs no).¹

Patients were randomly assigned (2:1) to receive ramucirumab 8 mg/kg plus BSC (n=197) or placebo plus BSC (n=95) every 14 days until disease progression or unacceptable toxicity, or until discontinuation criteria were met.¹ 

Inclusion Criteria

Patients were eligible for participation if they had

• received prior sorafenib treatment as the only systemic therapeutic intervention for advanced HCC for at least 14 days, and

• had discontinued sorafenib treatment ≥14 days prior to randomization.

The patient must also have either

• experienced radiographically confirmed disease progression during or after discontinuation of sorafenib therapy, or

• discontinued sorafenib treatment because of intolerance despite appropriate sorafenib management and supportive care.²

Prior Sorafenib Treatment

Baseline Patient Characteristics

The median duration of prior sorafenib was 4.11 months in both treatment arms. Additional details about prior sorafenib use are summarized in Table 1.

Table 1. Prior Sorafenib Treatment² 

Abbreviation: BSC = best supportive care. 

Efficacy Results

Efficacy results according to the reason for discontinuation of prior sorafenib are summarized in Table 2.

Table 2. Efficacy Results According to Reason for Prior Sorafenib Discontinuation²

Abbreviations: BSC = best supportive care; HR = hazard ratio; mo = month; NS = not significant; OS = overall survival; PBO = placebo; PFS = progression-free survival; RAM = ramucirumab. 

^a Estimated using the Kaplan-Meier method.

^b Hazard ratio and 95% CI (Wald) were estimated from unstratified Cox model.

^c Wald test of treatment-by-subgroup interaction from unstratified Cox model.

^d Two-sided p value from unstratified log-rank test.

References

1. Zhu AX, Kang YK, Yen CJ, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. Presented as an oral presentation at: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1-5, 2018; Chicago, IL. Abstract #4003. https://meetinglibrary.asco.org/record/159169/abstract

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

AFP = alpha-fetoprotein

BSC = best supportive care

ECOG = Eastern Cooperative Oncology Group

HCC = hepatocellular carcinoma

PS = performance status